Venus Remedies Limited has informed the Exchange regarding 'Disclosure of information received from promoter group companies regarding merger.'.

Nclt Scheme FiledStrategic Transactions View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.5%Reaction day

₹661.00

prior close

₹644.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.7%+6.1% vs market

Pharmaceuticals peers, median of 159sector-1.5%+5.0% vs sector

On the reaction day the stock moved 6.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

+0.0

15m

-2.3

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.5-2.7+6.1-1.5+5.0

Next day

+6.1-1.6+7.7-0.4+6.4

+6.1-1.7+7.9-0.5+6.7

+13.9-4.3+18.3-1.6+15.6

+18.5-2.1+20.6+0.3+18.2

+30.4-2.2+32.5-0.3+30.7

+34.6-5.3+40.0-2.7+37.4

15d

+32.0-3.9+35.8-3.6+35.6

+39.8-3.4+43.2-3.2+43.0

+51.0+11.9+39.1+5.4+45.6

+135.4+14.7+120.6+7.7+127.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies has disclosed that two promoter group companies, Sunev Pharma Solutions Pvt Ltd and Spine Software Systems Pvt Ltd, have approved a Scheme of Amalgamation for the merger of Sunev into Spine, subject to regulatory approvals. Sunev currently holds 17.21% of Venus Remedies' equity share capital, which will transfer to Spine once the scheme takes effect. The company clarified this is an internal promoter group restructuring with no change in control of Venus Remedies, and aggregate promoter group shareholding will remain unchanged. Venus Remedies itself is not a party to the scheme.

Likely market impact

Neutral for Venus Remedies shareholders — the merger is between promoter group entities and does not affect the company's business, control, or shareholding pattern. The 17.21% stake simply shifts from one promoter group entity to another within the same group.